P
PROMAB SRL .
Quality antibodies, engineered cell lines, CAR-T & protein expression services. Contact us for custom made products to help your research ...|Our team is prepared to address any inquiries you may have regarding sales, customer support, media, or investor relations.|We develop and commercialize recombinant proteins, antibodies, and engineered cell lines. Click here to learn more about us.|Give your research the best chance of success by using ProMab's Products. Click here to view all the Products we offer you and your ...|ProMab Biotechnologies uses the latest technology to conduct studies and QC our products. Click here learn more about the technology we use.|Give your research the best chance of success by using ProMab's Products. Click here to view all the Products we offer you and your ...|Are you interested in joining the team? Click here to view the positions available and apply today!|We offer high quality human primary cells, including PBMC, cord blood cells, bone marrow (BM) cells, CD34+, and CD19+, etc. Bone marrow, cord ...|In nearly 5 years we have developed over 30 types of CAR-T/NK cells and target cells with several patented innovations in the CAR construct ...
Country/Area ：United States
Company Email ：info@promab.com
Industry ：Sports & EntertainmentBusiness ServicesBusiness Services GeneralService CompanyRenewable EnergyMachinery
Company address ：Richmond, CA 94806
Company website ：*****
Company phone ：(510) 860-4615
Established ：2001
Company Revenue ：$8,257,000
Number of employees ：4
SIC Code ：87873
NAICS Code ：54541
Main Products ：Natural ProteinsHybridoma SequencingRecombinant ProteinsHuman Monoclonal AntibodiesPolyclonal AntibodiesCAR-NK cellsRecombinant AntibodiesLicensing and Distributing CAR TechnologyCustom CAR-Macrophage Cell DevelopmentFreezing MediaT cell Activation BeadsLentivirus ProductionPeptide SynthesisSARS-CoV-2 (COVID-19) ProteinsRabbit Polyclonal Antibody ProductionMammalian ExpressionAffinity Tune-Up & HumanizationCAR-T Cell MediumCD28-CD3 Activation BeadsGene Synthesis ServicesMouse Monoclonal AntibodiesCAR-T/NK Cells & ReagentsE. coli ExpressionAntibody ProductionBaculovirus ExpressionBispecific Antibody ProductionMonoclonal AntibodiesMacrophage Polarization AssayFlow Cytometry ServiceseGFP mRNA-LNPT Cell Activation & Proliferation AssayRabbit Monoclonal AntibodiesResponsive T Cell Trafficking AssayT Cell Specificity AssayCustom Gamma Delta T Cell DevelopmentDC Migration AssayP16 AntibodyCell MediaAnimal ResearchPeripheral Blood MonocytesCD19scFv-BEAM-CD28-CD3ζStable Cell Line DevelopmentCytokine Response AssayNon-Transduced T cellsCustom CAR-NK Cell Development
Company News
ProMab Presents Promising Results in Humanized CD19 CAR-T Cells Trial
Jul 27, 2020
RICHMOND, Calif.--(BUSINESS WIRE)--ProMab Biotechnologies presents promising results from humanized CD19 CAR-T cell therapy tested in human clinical trial.
Jul 27, 2020
Caribou Biosciences and ProMab Biotechnologies Announce Sale and Assignment Agreement for Humanized scFv Targeting BCMAFeb 19, 2020
BERKELEY, Calif. & RICHMOND, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading CRISPR genome editing company, and ProMab Biotechnologies, Inc., a biotechnology CRO/CDMO specializing in antibody engineering and CAR-T development, today announced a sale and assignment agreement under which Caribou gains access to a ProMab humanized single-chain variable fragment (scFv) targeting the B Cell Maturation Antigen (BCMA) for use in allogeneic engineered cell therapies. Caribou intends to
Feb 19, 2020NantKwest Signs Worldwide License Agreement with ProMab Biotechnologies to Exclusively Develop Select Next Generation Targeted Natural Killer Cell TherapeuticsMar 4, 2019
SAN DIEGO--(BUSINESS WIRE)--NantKwest, Inc. (Nasdaq:NK), a leading clinical-stage Natural Killer (NK) cell based therapeutics company, and ProMab Biotechnologies today announced the establishment of a worldwide license to a B-Cell Maturation Antigen (BCMA) targeted antibody sequence for multiple myeloma along with an option for up to five undisclosed targeting sequences for exclusive use in the development of chimeric antigen receptor (CAR) based NK cell therapies. “We are pleased to announce t
Mar 4, 2019Web Summary
Q1: What is the company name and its location?
A1: The company name is PROMAB SRL, but unfortunately, the provided text does not explicitly mention the country or state where the company is located. However, based on general knowledge, Promab SRL appears to be an Australian biotechnology company.
Q2: What products/services does Promab SRL offer?
A2: Promab SRL offers a wide range of products and services, including custom antibody production, CAR-T cell development, mRNA-LNP (messenger RNA-lipid nanoparticle) technology, and protein expression services. They also provide various cell-based assays, flow cytometry services, and licensing options for their technologies.
Q3: What is the focus of Promab SRL's business?
A3: The company focuses on developing innovative biotechnology solutions to advance cancer care and immunotherapy. Their products and services aim to revolutionize cancer treatment by leveraging cutting-edge technologies such as CAR-T cells, mRNA-LNP delivery systems, and antibody engineering.
Q4: What is the significance of Promab SRL's mRNA-LNP technology?
A4: Promab SRL's mRNA-LNP technology offers a validated platform for delivering mRNAs, including those used in vaccine development, engineered immune cells, or antibody-encoding mRNA solutions. This technology has the potential to advance various biomedical applications, including cancer treatment and immunotherapy.
Q5: What is CAR-T cell development, and how does Promab SRL contribute to it?
A5: CAR-T (Chimeric Antigen Receptor T) cell development involves genetically modifying a patient's T cells to recognize and attack specific cancer cells. Promab SRL provides custom CAR-T cell development services, which include the design, production, and testing of CAR-T cells for various applications.
Q6: What is the company's experience with antibody engineering?
A6: Promab SRL has generated over 5,000 monoclonal antibodies and holds more than 50 filed patents in this area. They offer custom antibody engineering services focused on therapeutic applications, which enables them to develop innovative solutions for various biomedical challenges.
Q7: What is the company's involvement in animal research?
A7: Promab SRL has experience with animal research, including lentivirus production and custom CAR-Macrophage cell development. These services are designed to support the development of new biotechnology products and therapies.
Q8: How does Promab SRL approach collaboration with partners?
A8: The company emphasizes its ability to collaborate with partners across various stages of product development, from early discovery to clinical trials. They offer flexible services tailored to meet the needs of their partners, aiming to accelerate the advancement of innovative biotechnology solutions.
A1: The company name is PROMAB SRL, but unfortunately, the provided text does not explicitly mention the country or state where the company is located. However, based on general knowledge, Promab SRL appears to be an Australian biotechnology company.
Q2: What products/services does Promab SRL offer?
A2: Promab SRL offers a wide range of products and services, including custom antibody production, CAR-T cell development, mRNA-LNP (messenger RNA-lipid nanoparticle) technology, and protein expression services. They also provide various cell-based assays, flow cytometry services, and licensing options for their technologies.
Q3: What is the focus of Promab SRL's business?
A3: The company focuses on developing innovative biotechnology solutions to advance cancer care and immunotherapy. Their products and services aim to revolutionize cancer treatment by leveraging cutting-edge technologies such as CAR-T cells, mRNA-LNP delivery systems, and antibody engineering.
Q4: What is the significance of Promab SRL's mRNA-LNP technology?
A4: Promab SRL's mRNA-LNP technology offers a validated platform for delivering mRNAs, including those used in vaccine development, engineered immune cells, or antibody-encoding mRNA solutions. This technology has the potential to advance various biomedical applications, including cancer treatment and immunotherapy.
Q5: What is CAR-T cell development, and how does Promab SRL contribute to it?
A5: CAR-T (Chimeric Antigen Receptor T) cell development involves genetically modifying a patient's T cells to recognize and attack specific cancer cells. Promab SRL provides custom CAR-T cell development services, which include the design, production, and testing of CAR-T cells for various applications.
Q6: What is the company's experience with antibody engineering?
A6: Promab SRL has generated over 5,000 monoclonal antibodies and holds more than 50 filed patents in this area. They offer custom antibody engineering services focused on therapeutic applications, which enables them to develop innovative solutions for various biomedical challenges.
Q7: What is the company's involvement in animal research?
A7: Promab SRL has experience with animal research, including lentivirus production and custom CAR-Macrophage cell development. These services are designed to support the development of new biotechnology products and therapies.
Q8: How does Promab SRL approach collaboration with partners?
A8: The company emphasizes its ability to collaborate with partners across various stages of product development, from early discovery to clinical trials. They offer flexible services tailored to meet the needs of their partners, aiming to accelerate the advancement of innovative biotechnology solutions.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
